Comprehensive Report on LTI-03: A Novel Peptide Therapeutic for Idiopathic Pulmonary Fibrosis

I. Introduction to LTI-03

A. Overview and Chemical Identity of LTI-03

LTI-03 is an investigational biotech product identified as a caveolin-1 Scaffolding Domain 7-Mer peptide.[1] This nomenclature reflects its origin and chemical nature. The compound is also known by several synonyms, including CSP-7 (Caveolin Scaffolding Domain Peptide 7-mer) and its specific amino acid sequence, PHE-THR-THR-PHE-THR-VAL-THR.[2] These alternative names are frequently used in scientific literature and company communications.

Key chemical and regulatory identifiers for LTI-03 are crucial for its precise identification and for tracking its development. These include:

• DrugBank ID: DB18491.[5] This accession number allows for standardized cross-referencing in the DrugBank database, a comprehensive resource for drug information.
• CAS Number: 1504575-10-3.[2] The Chemical Abstracts Service (CAS) registry number is a unique numerical identifier assigned to every chemical substance, ensuring unambiguous identification.
• FDA UNII (Unique Ingredient Identifier): JE7G34JYW4.[1] This identifier is utilized by the U.S. Food and Drug Administration (FDA) for substance registration and tracking.